Literature DB >> 10459993

Octreotide for nausea and vomiting after chemotherapy and stem-cell transplantation.

G Nordesjö-Haglund, B Lönnqvist, G Lindberg, E Hellström-Lindberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10459993     DOI： 10.1016/S0140-6736(05)76666-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  The use of octreotide to manage symptoms of bronchorrhea: a case report.

Authors:  Meera Pahuja; Ray W Shepherd; Laurel J Lyckholm
Journal:  J Pain Symptom Manage       Date:  2013-09-12       Impact factor: 3.612

Review 2.  Established and potential therapeutic applications of octreotide in palliative care.

Authors:  Eric E Prommer
Journal:  Support Care Cancer       Date:  2008-02-07       Impact factor: 3.603

3.  A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.

Authors:  Sendhilnathan Ramalingam; Sharareh Siamakpour-Reihani; Lauren Bohannan; Yi Ren; Alexander Sibley; Jeff Sheng; Li Ma; Andrew B Nixon; Jing Lyu; Daniel C Parker; James Bain; Michael Muehlbauer; Olga Ilkayeva; Virginia Byers Kraus; Janet L Huebner; Thomas Spitzer; Jami Brown; Jonathan U Peled; Marcel van den Brink; Antonio Gomes; Taewoong Choi; Cristina Gasparetto; Mitchell Horwitz; Gwynn Long; Richard Lopez; David Rizzieri; Stefanie Sarantopoulos; Nelson Chao; Anthony D Sung
Journal:  PLoS One       Date:  2021-06-25       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.